Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454637 | 1.00 | LMNA (0.47) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7546641 | 0.83 | LMNA (0.41) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL31689531 | 0.83 | LMNA (0.41) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5524384 | 0.83 | ALDH1A1 (0.50) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL394533 | 0.81 | LMNA (0.49) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL29421567 | 0.81 | LMNA (0.49) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL851152 | 0.81 | CA2 (0.55) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL994541 | 0.80 | TDP1 (0.61) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3194901 | 0.80 | CA2 (0.43) | ALDH1A1MEN1KMT2ATDP1HSD17B10 | |
| SCHEMBL830828 | 0.79 | LMNA (0.51) | LMNAALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109608369-B | Sulfonyl ester group anthraquinone derivative and preparation method and application thereof | 广西大学 | 2021-04-09 | — | — | CN | claimed |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313879-A1 | Fluorescent Probe for Detecting Peptide Bond Hydrolase | THE UNIVERSITY OF TOKYO (JP) | 2025-10-09 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119855814-A | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| CN-1897944-A | Benzenesulfonamido-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity | AGOURON PHARMA (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076644-A2 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021806-A1 | ARYLSULPHONYLSTILBENE DERIVATIVES FOR TREATMENT OF INSOMNIA AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CCR2, CXCR2, CCR1 | LMNA 4631/4885ALDH1A1 2327/4885MEN1 4873/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | LMNA 3884/4885ALDH1A1 742/4885MEN1 1826/4885 |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | LMNA 4750/4885ALDH1A1 2745/4885MEN1 3711/4885 |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | LMNA 3266/4885ALDH1A1 70/4885MEN1 2592/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | LMNA 2401/4885ALDH1A1 1720/4885MEN1 3931/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | LMNA 4750/4885ALDH1A1 2745/4885MEN1 3711/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | LMNA 4750/4885ALDH1A1 2745/4885MEN1 3711/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | LMNA 4013/4885ALDH1A1 2857/4885MEN1 2641/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | LMNA 2401/4885ALDH1A1 1720/4885MEN1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.